Key Points
- CEO Benjamin Palleiko sold 6,693 shares on March 9 at an average price of $16.08 for proceeds of $107,623, trimming his stake by 1.46% to 451,815 shares valued at about $7.27 million.
- KalVista shares opened at $18.44, trade above their 50- and 200-day moving averages ($15.66 and $14.19), have a market cap of roughly $932 million and a 52-week range of $9.23 to $19.00.
- Analyst coverage is skewed positive with seven Buys and one Sell, a consensus rating of "Moderate Buy" and an average price target of about $29.40, while individual targets range from a Weiss sell to HC Wainwright's $37 target.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin Palleiko sold 6,693 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $16.08, for a total transaction of $107,623.44. Following the completion of the transaction, the chief executive officer directly owned 451,815 shares of the company's stock, valued at approximately $7,265,185.20. The trade was a 1.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
KalVista Pharmaceuticals Stock Performance
Shares of KalVista Pharmaceuticals stock opened at $18.44 on Wednesday. The company's 50 day moving average price is $15.66 and its two-hundred day moving average price is $14.19. The firm has a market capitalization of $932.14 million, a P/E ratio of -4.67 and a beta of -0.35. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.23 and a fifty-two week high of $19.00. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.
Institutional Trading of KalVista Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC bought a new position in KalVista Pharmaceuticals during the 1st quarter worth approximately $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of KalVista Pharmaceuticals by 13.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company's stock valued at $281,000 after purchasing an additional 2,939 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of KalVista Pharmaceuticals by 3.7% during the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company's stock worth $3,923,000 after buying an additional 12,263 shares during the period. Profund Advisors LLC acquired a new stake in shares of KalVista Pharmaceuticals during the second quarter worth $113,000. Finally, Nan Fung Trinity HK Ltd. bought a new position in KalVista Pharmaceuticals during the second quarter worth $1,747,000.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on KALV shares. HC Wainwright boosted their price objective on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a "buy" rating in a research report on Friday, January 9th. Citigroup restated a "market outperform" rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen raised shares of KalVista Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, December 6th. Finally, Citizens Jmp dropped their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a "market outperform" rating for the company in a research note on Tuesday, November 11th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $29.40.
Check Out Our Latest Research Report on KALV
About KalVista Pharmaceuticals
(
Get Free Report)
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
